Three dead in attacks against Ebola response centers in Congo
Three health workers were killed and several injured in attacks against two Ebola response centers in eastern Congo early on Thursday, authorities and health services said.
by Kai J. Rogers, Bethany Brunton, Laura Mallinger, Dana Bohan, Kristina M. Sevcik, Jing Chen, Natalie Ruggio, Wendy Maury BackgroundEbolavirus (EBOV) outbreaks, while sporadic, cause tremendous morbidity and mortality. No therapeutics or vaccines are currently licensed; however, a vaccine has shown promise in clinical trials. A critical step towards development of effective therapeutics is a better understanding of factors that govern host susceptibility to this pathogen. As macrophages are an important cell population targeted during virus replication, we explore the effect of cytokine polarization on macrophage infectio...
Swati Gupta ’97 M.P.H. and Anant Shah ’07 M.P.H. are at the forefront of the global fight against Ebola.
December 10, 2019—BRONX, NY— Researchers atAlbert Einstein College of Medicine secured $178 million from the National Institutes of Health in federal fiscal year 2019, marking the largest annual total in the institution’s history (excluding supplemental stimulus funding distributed as a part of the American Recovery and Reinvestment Act of 2009). Major grants included those to lead international consortiums to study Ebola and HIV, as well as those focusing on neuroscience, genetics, and improving health among minority groups.
[The New Humanitarian] GOMA, Democratic Republic of Congo -The Democratic Republic of Congo's deadliest ever Ebola outbreak has shown signs of slowing in recent weeks, but militia attacks, anti-UN protests, and chronic community distrust are undermining the 16-month effort to end the epidemic.
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the b...
Two experimental drugs each reduced the risk of death from Ebola when tested in an outbreak in the Democratic Republic of Congo.
[New Times] Rwanda and the Democratic Republic of the Congo Sunday unveiled a massive vaccination campaign against Ebola Virus Disease (EVD) for their residents who live within the vicinity of a possible Ebola outbreak.
An Ebola survivor has fallen ill with the disease for a second time in eastern Congo, the Congolese health authorities said on Sunday, saying it was not yet clear if it was a case of relapse or reinfection.
Up to 200,000 Regimens of Janssen ’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
[Daily News] THE East African Legislative Assembly (EALA) has adopted a report of the Committee on General Purpose on the oversight activity assessing levels of preparedness of partner states in management of epidemics, particularly Ebola and Dengue.